Literature DB >> 26768743

Current State of Stem Cell Therapy for Ischemic Heart Disease.

Thomas J Povsic1.   

Abstract

Improvements in the care of patients with ischemic cardiovascular disease have led to improved survival but also a burgeoning population of patients with advanced ischemic heart disease. Cell therapies offer a novel approach toward cardiac "rejuvenation" via stimulation of new blood vessel growth, enhancing tissue perfusion, and via preservation or even regeneration of myocardial tissue, leading to improvements in cardiac performance after myocardial infarction and in patients with advanced heart failure. Here, we summarize and offer some thoughts on the state of the field of cell therapy for ischemic heart disease, targeting three separate conditions that have been the subject of significant clinical research: enhancing left ventricular recovery after MI, improving outcomes and symptoms in patients with congestive heart failure (CHF), and treatment of patients with refractory angina, despite maximal medical therapy.

Entities:  

Keywords:  Congestive heart failure; Coronary artery disease; Ischemic heart disease; Progenitor cells; Refractory angina; Stem cells

Mesh:

Year:  2016        PMID: 26768743     DOI: 10.1007/s11886-015-0693-6

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  101 in total

1.  Intracoronary infusion of mononuclear cells from bone marrow or peripheral blood compared with standard therapy in patients after acute myocardial infarction treated by primary percutaneous coronary intervention: results of the randomized controlled HEBE trial.

Authors:  Alexander Hirsch; Robin Nijveldt; Pieter A van der Vleuten; Jan G P Tijssen; Willem J van der Giessen; René A Tio; Johannes Waltenberger; Jurrien M ten Berg; Pieter A Doevendans; Wim R M Aengevaeren; Jaap Jan Zwaginga; Bart J Biemond; Albert C van Rossum; Jan J Piek; Felix Zijlstra
Journal:  Eur Heart J       Date:  2010-12-10       Impact factor: 29.983

2.  Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial.

Authors:  Gerd P Meyer; Kai C Wollert; Joachim Lotz; Jan Steffens; Peter Lippolt; Stephanie Fichtner; Hartmut Hecker; Arnd Schaefer; Lubomir Arseniev; Bernd Hertenstein; Arnold Ganser; Helmut Drexler
Journal:  Circulation       Date:  2006-03-06       Impact factor: 29.690

3.  Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.

Authors:  Peter H Stone; Nikolay A Gratsiansky; Alexey Blokhin; I-Zu Huang; Lixin Meng
Journal:  J Am Coll Cardiol       Date:  2006-06-15       Impact factor: 24.094

4.  Mobilization of endothelial progenitor cells in patients with acute myocardial infarction.

Authors:  S Shintani; T Murohara; H Ikeda; T Ueno; T Honma; A Katoh; K Sasaki; T Shimada; Y Oike; T Imaizumi
Journal:  Circulation       Date:  2001-06-12       Impact factor: 29.690

5.  Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction.

Authors:  Volker Schächinger; Sandra Erbs; Albrecht Elsässer; Werner Haberbosch; Rainer Hambrecht; Hans Hölschermann; Jiangtao Yu; Roberto Corti; Detlef G Mathey; Christian W Hamm; Tim Süselbeck; Birgit Assmus; Torsten Tonn; Stefanie Dimmeler; Andreas M Zeiher
Journal:  N Engl J Med       Date:  2006-09-21       Impact factor: 91.245

6.  Chimerism of the transplanted heart.

Authors:  Federico Quaini; Konrad Urbanek; Antonio P Beltrami; Nicoletta Finato; Carlo A Beltrami; Bernardo Nadal-Ginard; Jan Kajstura; Annarosa Leri; Piero Anversa
Journal:  N Engl J Med       Date:  2002-01-03       Impact factor: 91.245

7.  Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT-CAD trial).

Authors:  Hung-Fat Tse; Sukumaran Thambar; Yok-Lam Kwong; Philip Rowlings; Greg Bellamy; Jane McCrohon; Paul Thomas; Bruce Bastian; John K F Chan; Gladys Lo; Chi-Lai Ho; Wing-Sze Chan; Raymond Y Kwong; Anthony Parker; Thomas H Hauser; Jenny Chan; Daniel Y T Fong; Chu-Pak Lau
Journal:  Eur Heart J       Date:  2007-11-05       Impact factor: 29.983

8.  Regenerating functional myocardium: improved performance after skeletal myoblast transplantation.

Authors:  D A Taylor; B Z Atkins; P Hungspreugs; T R Jones; M C Reedy; K A Hutcheson; D D Glower; W E Kraus
Journal:  Nat Med       Date:  1998-08       Impact factor: 53.440

9.  A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: design of the RENEW study.

Authors:  Thomas J Povsic; Candice Junge; Adel Nada; Richard A Schatz; Robert A Harrington; Charles J Davidson; F David Fortuin; Dean J Kereiakes; Farrell O Mendelsohn; Warren Sherman; Gary L Schaer; Christopher J White; Duncan Stewart; Kenneth Story; Douglas W Losordo; Timothy D Henry
Journal:  Am Heart J       Date:  2013-04-19       Impact factor: 4.749

10.  Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial.

Authors:  Douglas W Losordo; Richard A Schatz; Christopher J White; James E Udelson; Vimal Veereshwarayya; Michelle Durgin; Kian Keong Poh; Robert Weinstein; Marianne Kearney; Muqtada Chaudhry; Aaron Burg; Liz Eaton; Lindsay Heyd; Tina Thorne; Leon Shturman; Peter Hoffmeister; Ken Story; Victor Zak; Douglas Dowling; Jay H Traverse; Rachel E Olson; Janice Flanagan; Donata Sodano; Toshinori Murayama; Atsuhiko Kawamoto; Kengo Fukushima Kusano; Jill Wollins; Frederick Welt; Pinak Shah; Peter Soukas; Takayuki Asahara; Timothy D Henry
Journal:  Circulation       Date:  2007-06-11       Impact factor: 29.690

View more
  6 in total

1.  Anti-PEG Antibodies Inhibit the Anticoagulant Activity of PEGylated Aptamers.

Authors:  Angelo Moreno; George A Pitoc; Nancy J Ganson; Juliana M Layzer; Michael S Hershfield; Alice F Tarantal; Bruce A Sullenger
Journal:  Cell Chem Biol       Date:  2019-02-28       Impact factor: 8.116

2.  A Novel Role for CAMKK1 in the Regulation of the Mesenchymal Stem Cell Secretome.

Authors:  Feng Dong; Shyam Patnaik; Zhong-Hui Duan; Matthew Kiedrowski; Marc S Penn; Maritza E Mayorga
Journal:  Stem Cells Transl Med       Date:  2017-07-08       Impact factor: 6.940

3.  Effect of stem cell transplantation on patients with ischemic heart failure: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Yixuan Wang; Fen Xu; Jingwei Ma; Jiawei Shi; Si Chen; Zongtao Liu; Junwei Liu
Journal:  Stem Cell Res Ther       Date:  2019-04-18       Impact factor: 6.832

4.  Therapeutic effects of coronary granulocyte colony-stimulating factor on rats with chronic ischemic heart disease.

Authors:  Pengcheng Ren; Ming Zhang; Shuren Dai
Journal:  Open Life Sci       Date:  2020-10-20       Impact factor: 0.938

5.  Stem cell therapy targeting the right ventricle in pulmonary arterial hypertension: is it a potential avenue of therapy?

Authors:  Fanny Loisel; Bastien Provost; François Haddad; Julien Guihaire; Myriam Amsallem; Bojan Vrtovec; Elie Fadel; Georges Uzan; Olaf Mercier
Journal:  Pulm Circ       Date:  2018-02-26       Impact factor: 3.017

6.  Midterm outcomes of transmyocardial laser revascularization with intramyocardial injection of adipose derived stromal cells for severe refractory angina.

Authors:  Janusz Konstanty-Kalandyk; Krzysztof Bartuś; Jacek Piątek; Venkat Vuddanda; Randall Lee; Anna Kędziora; Jerzy Sadowski; Dhanunjaya Lakkireddy; Bogusław Kapelak
Journal:  Postepy Kardiol Interwencyjnej       Date:  2018-06-19       Impact factor: 1.426

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.